|[July 23, 2014]
Research and Markets: Global Women's Health Market 2014-2018
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/scjzgs/global_womens)
has announced the addition of the "Global
Women's Health Market 2014-2018" report to their offering.
The Global Women's Health market will grow at a CAGR of 3.52 percent
over the period 2013-2018.
Women experience physiological and emotional issues during different
phases of their life cycle due to hormonal changes. Women's health is
especially referred to where reproductive health is involved. According
to the Society for Women's Health Research in the US, issues specific to
the human female anatomy are defined as women's health. The biological
mechanisms influence the clinical course of diseases and disorders
differently in women when compared to men. Some of the main women's
health disorders inlude infertility, menopause, endometriosis and
polycystic ovarian syndrome as well as urological disorders and cancers
such as breast cancer, cervical cancer, endometrial cancer, and ovarian
cancer. In addition, contraception plays an important role in women's
health for many reasons, so this too is also categorized under women's
To calculate the market size, the report considers revenue generated
from the sales of various products used for the wellbeing of women,
which are listed below based on their application segment:
Postmenopausal Osteoporosis (Drugs)
Hormonal Contraceptives (Drugs and Devices)
Polycystic Ovary Syndrome (Drugs)
The report, the Global Women's Health Market 2014-2018, has been
prepared based on an in-depth market analysis with inputs from industry
experts. The report covers the Americas, the EMEA, and the APAC regions;
it also covers the Global Women's Health market landscape and its growth
prospects in the coming years. The report also includes a discussion of
the key vendors operating in this market.
Eli Lilly and Co.
Merck & Co.
According to the report, the growth of the Global Women's Health market
is curtailed by some serious challenges. One of the main challenges is
the patent expiry of major blockbuster drugs during the forecast period.
Some of the patent expiries of top leading products include Bayer's
Mirena and Yaz, Eli Lilly's Evista, and F. Hoffmann-La Roche's Boniva.
For more information visit http://www.researchandmarkets.com/research/scjzgs/global_womens
[ Back To TMCnet.com's Homepage ]